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Abstract
We aim to evaluate the epidemiology and outcome of gram-negative prosthetic joint infection (GN-PJI) treated with debridement, antibiotics
and implant retention (DAIR), identify factors predictive of failure, and determine the impact of ciproﬂoxacin use on prognosis.We performed
a retrospective, multicentre, observational study of GN-PJI diagnosed from 2003 through to 2010 in 16 Spanish hospitals. We deﬁne failure as
persistence or reappearance of the inﬂammatory joint signs during follow-up, leading to unplanned surgery or repeat debridement >30 days
from the index surgery related death, or suppressive antimicrobial therapy. Parameters predicting failure were analysed with a Cox regression
model. A total of 242 patients (33% men; median age 76 years, interquartile range (IQR) 68–81) with 242 episodes of GN-PJI were studied.
The implants included 150 (62%) hip, 85 (35%) knee, ﬁve (2%) shoulder and two (1%) elbow prostheses. There were 189 (78%) acute
infections. Causative microorganisms were Enterobacteriaceae in 78%, Pseudomonas spp. in 20%, and other gram-negative bacilli in 2%.
Overall, 19% of isolates were ciproﬂoxacin resistant. DAIR was used in 174 (72%) cases, with an overall success rate of 68%, which increased
to 79% after a median of 25 months’ follow-up in ciproﬂoxacin-susceptible GN-PJIs treated with ciproﬂoxacin. Ciproﬂoxacin treatment
exhibited an independent protective effect (adjusted hazard ratio (aHR) 0.23; 95%CI, 0.13–0.40; p <0.001), whereas chronic renal impairment
predicted failure (aHR, 2.56; 95% CI, 1.14–5.77; p 0.0232). Our results conﬁrm a 79% success rate in ciproﬂoxacin-susceptible GN-PJI treated
with debridement, ciproﬂoxacin and implant retention. New therapeutic strategies are needed for ciproﬂoxacin-resistant PJI.
Keywords: Ciproﬂoxacin, debridement, gram-negative bacteria, prognosis, prosthetic joint infection
Original Submission: 2 February 2014; Revised Submission: 7 April 2014; Accepted: 18 April 2014
Editor: J.-M. Rolain
Article published online: 26 April 2014
Clin Microbiol Infect 2014; 20: O911–O919
10.1111/1469-0691.12649
Corresponding author: D. Rodrıguez-Pardo, Infectious Diseases Department, Hospital Universitari Vall d’Hebron, Pg. Vall d’Hebron 119-129, 08035
Barcelona, Spain
E-mail:dolorodriguez@vhebron.net
*Members of the Spanish Network for Research in Infectious Diseases (REIPI) Group for the Study of Prosthetic Infection are listed in the Appendix.
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases
ORIGINAL ARTICLE INFECTIOUS DISEASES
Introduction
Prosthetic joint infection (PJI) is an uncommon complication
(1–2%) of joint replacement surgery associated with high
morbidity and medical expenditure [1,2]. The most
frequently isolated microorganisms are gram-positive
cocci. However, gram-negative bacteria (GNB) constitute
10–23% of all episodes, and these infections are often acute
[3–5].
In patients with acute PJI and a stable implant, conservative
management can be attempted, consisting of prompt debride-
ment and implant retention, combined with prolonged
pathogen-targeted therapy with antibiotics active against
surface-adhering microorganisms [4–6]. This conservative
approach has a success rate for staphylococcal infections
ranging from 55% to over 75% [7–9]. In the case of
gram-negative PJI (GN-PJI) there is little published experi-
ence, the data regarding treatment efﬁcacy are inconsistent
[3,10–15] and often published series include mixed infections
caused by both gram-positive and gram-negative bacteria;
hence, it is difﬁcult to know the true success rates in GN-PJI
treated with debridement, antibiotics and implant retention
(DAIR).
Focusing on antibiotic treatment of GN-PJIs, to our
knowledge, there are no available data from experimental
in vitro and animal studies that support the role of ﬂuoro-
quinoles except the experience reported by Tanaka et al.
[16] that revealed the strong bactericidal activity of fuoroqu-
inolones over a leucine-requiring mutant Pseudomonas aeru-
ginosa. The combinations of cefepime-oﬂoxacin or
ciproﬂoxacin and ceftazidime-ciproﬂoxacin proved to be
successful in the treatment of P. aeruginosa bone and joint
infections [14,17] and ciproﬂoxacin use has been associated
with a better outcome when treating susceptible GNB in PJIs
[10,13,18]. However, the growing resistance of GNBs to
ciproﬂoxacin may increasingly complicate GN-PJI treatment
and outcome.
We present a large multicentre series of GN-PJIs treated
with DAIR. We aimed to assess the efﬁcacy of DAIR, identify
predictive factors of failure, and establish the impact of
ciproﬂoxacin use on the prognosis.
Methods
Study design
A retrospective observational cohort study performed in 16
Spanish hospitals in the framework of the Spanish Network for
Research in Infectious Disease (REIPI).
Study population
Cases were identiﬁed by searching the databases of previously
recorded consecutive PJIs or the general archives of each
participating hospital. All PJIs originally caused by GNB and
diagnosed from January 2003 through to December 2010 were
examined. Polymicrobial infections caused by more than one
GNB were included, but those caused by GNB and
gram-positive cocci were excluded to assess the true impact
of GNB in PJI. Patients in whom GNB did not cause the original
PJI, but participated later as a superinfecting microorganism,
were excluded.
Data collection
The following data were recorded: demographics, co-morbid-
ities, site of implant, date of implantation, date of symptom
onset, clinical manifestations, leukocyte count, C-reactive
protein (CRP) level at the diagnosis, preoperative radiology
evaluation, microbiological data, surgical treatment, antimicro-
bial therapy and patient outcome.
All information was entered into a Microsoft Access 2007
database. All cases were critically reviewed by DR-P. and CP.
All inconsistent data were checked by the investigator at each
collaborating hospital. Institutional review board approval was
not required because patients were treated according to local
standards of care; no clinical interventions were made based
on the data collection.
Microbiological methods
Periprosthetic surgical cultures or joint ﬂuid aspirates were
inoculated onto blood agar enriched with 5% sterile bovine
blood, chocolate agar and McConkey agar plates, and brain
heart and thioglycolate broth for enriched and anaerobe
culture, respectively. Microorganisms isolated were identiﬁed
by conventional biochemical and metabolic tests, in most
cases using an automatic system (Vitek or API System from
bioMerieux Inc., Marcy l’Etoile, France or MicroScan Walk-
Away System from Siemens Healthcare Diagnostics, Munich,
Germany). Antimicrobial susceptibility was assessed by
methods used in each centre (disk-diffusion, E-test or
microdilution technique), according to Clinical and Labora-
tory Standards Institute (CLSI) recommendations.
Deﬁnitions
The diagnosis of GN-PJI was established when ≥2 intraop-
erative cultures yielded the same GNB, a positive blood
culture yielded GNB in the presence of clinical symptoms
and signs of PJI, or there was evidence of purulence
surrounding the prosthesis and GNB growth in a single
culture. PJI type was assigned according to the Tsukayama
criteria [19].
ª2014 The Authors
Clinical Microbiology and Infection ª2014 European Society of Clinical Microbiology and Infectious Diseases, CMI, 20, O911–O919
O912 Clinical Microbiology and Infection, Volume 20 Number 11, November 2014 CMI
Clinical and surgical management
The decision to treat by debridement and the choice of
antibiotic therapy were made by the attending medical team.
DAIR management consists of prompt debridement with
thorough removal of necrotic tissue, purulent collections and
debris around the implant, exchange of mobile arthroplasty
parts when possible, and prosthesis retention. After obtaining
tissue cultures, intravenous broad-spectrum antibiotics are
administered, and treatment is adjusted according to suscep-
tibility. Intravenous administration is followed by oral antibi-
otics according to published treatment recommendations
[2,5]. In all cases, a staff member of the infectious diseases
department of each hospital participated in managing these
patients. For the purposes of the present study, DAIR was
considered to start with the ﬁrst debridement surgery.
Antimicrobials administered before this procedure were not
considered a part of DAIR.
Outcome and follow-up
We performed an overall failure analysis, in which failure was
deﬁned as persistence or reappearance of inﬂammatory joint
signs during follow-up, leading to unplanned surgery. Infec-
tion-related death, a second debridement >30 days after the
ﬁrst, prosthesis removal for any cause (including orthopaedic
reasons) within the ﬁrst 2 years of follow-up and need for
suppressive antimicrobial therapy were also considered failure.
In addition, a subanalysis creating a composite variable was
performed to explore patient outcome based on whether or
not they fulﬁlled Zimmerli’s classiﬁcation algorithm [2], which
states that DAIR is a reasonable option for patients who
underwent debridement within 21 days after symptom onset,
presented with infection within 3 months after implantation (in
the absence of haematogenous PJI, which was managed as an
acute infection), had a stable prosthesis, and received an agent
(ciproﬂoxacin in our case) with activity against bioﬁlm
microorganisms.
Statistical analysis
Categorical variables are expressed as count and percentage,
and quantitative data as median and interquartile range (IQR).
The chi-square test or Fisher exact test was used to compare
distribution of categorical variables and the Student t-test or
Mann–Whitney U-test for continuous variables, as appropriate.
A p-value of <0.05 was considered statistically signiﬁcant.
A Kaplan–Meier curve was performed to determine rela-
tionships between treatment failures after DAIR and treatment
with ciproﬂoxacin in susceptible isolates.
A Cox regression model was applied to identify variables
associated with overall failure using the DAIR approach.
Variables with p <0.1 on univariate analysis were included in
the multivariate models. In addition, variables with p >0.1 and
considered clinically relevant based on experience and pub-
lished data were forced into the multivariate model to
investigate their effect. Ciproﬂoxacin treatment in susceptible
cases was maintained in the ﬁnal model as a ﬁxed variable.
Because antibiotic therapy duration may have been shortened
in cases failing prematurely, and this would not actually be the
cause of failure but its consequence, this variable was not
included in the model. Signiﬁcant interactions between
variables were ruled out. Statistical analyses were performed
with SPSS, version 15.0 (SPSS, Chicago, IL, USA).
Results
Study population and clinical presentation
Among 2015 PJIs occurring over the 8-year study period, 242
(12%) PJIs in 242 patients were originally caused by GNB. The
median age of the study patients was 76 years (IQR, 68–81).
The implants included 150 (62%) hip, 85 (35%) knee, ﬁve (2%)
shoulder and two (1%) elbow prostheses. Primary implants
accounted for 173 (71%) and revision prostheses for 69 (29%)
cases. Demographic data, co-morbid conditions, risk factors
predisposing to PJI and symptoms at presentation are shown in
Table 1. DAIR was the most common surgical strategy, applied
in 174 (72%) episodes. For the present study, analyses were
carried out including the 174 PJIs treated with DAIR. We
mention that 24 out of our 174 patients treated with DAIR had
been previously published [10,11,18].
Analysis of patients treated with DAIR
Patients managed with DAIR had acute infection in 154 (88%)
cases (130 (75%) early postoperative and 24 (14%) haemat-
ogenous) and late-chronic infection in 20 (11%) cases, although
symptom onset occurred between 31 and 90 days after
implant placement in 12 of these 20 patients. The median time
from prosthesis placement to symptom onset was 13 days
(IQR, 7.2–18) in early infections and 65 days (IQR, 46–1119) in
late-chronic infections.
Microbiological ﬁndings. Among 174 GN-PJIs, 34 were polymi-
crobial GNB infections (two different GNBs in 31 and three
different GNBs in three cases), accounting for a total of 211
isolates (Table 2). Polymicrobial GNB infection was more
frequent in pseudomonal PJI (14 of 43, 33%) than in infections
caused by other GNBs (20 of 131, 14.5%) (p 0.013). Blood
culture was positive in 11 GNB PJIs.
Overall, 41 of 211 (19%) GNB isolates were ciproﬂoxacin
resistant, and the percentage was similar in pseudomonal PJI
(seven of 43, 16%). Extended-spectrum beta-lactamase
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(ESBL)-producing Enterobacteriaceae accounted for 16 of 211
(8%) isolates (11 Escherichia coli, four Klebsiella pneumoniae and
one Enterobacter aerogenes), among which 11 (69%) were
ciproﬂoxacin resistant.
Medical treatment. Once tissue specimens had been obtained,
intravenous broad-spectrum antibiotics were administered,
including an anti-pseudomonal cephalosporin or a carbape-
nem associated with vancomycin in the case of suspicion of
methicillin-resistant Staphylococcus aureus infection. Ther-
apy was then adjusted according to the susceptibility pattern
of the bacteria isolated from intraoperative cul-
tures. Median duration of antibiotic treatment was 70 days
(IQR, 43–96): median intravenous treatment, 14 days (IQR,
6–23); oral antibiotics, 58 days (IQR, 27–90). The intrave-
nous antibiotic regimens used are summarized in
Table 3. The oral antibiotics prescribed included ciproﬂox-
acin in 111, cotrimoxazole in eight and beta-lactams in seven
patients.
Among 139/174 (80%) cases of ciproﬂoxacin-susceptible
GN-PJI, 124/139 (89%) were treated with ciproﬂoxacin for a
median of 69 days (IQR, 45–90).
Patients with Pseudomonas spp. PJI were treated for a
median of 60 days (IQR, 43–92). An initial combination of two
antibiotics was used in 25/43 cases of pseudomonal PJI
(carbapenem or other antipseudomonal beta-lactam plus
ciproﬂoxacin in 21, antipseudomonal beta-lactam plus amino-
glycoside in four), an antipseudomonal beta-lactam in nine, a
carbapenem in six and ciproﬂoxacin in three. The median
duration of intravenous treatment was 18 days (IQR, 12–28).
In 33/43 (77%) cases, intravenous therapy was followed by oral
ciproﬂoxacin for a median of 43 days (IQR, 26–79).
TABLE 1. Demographic data, co-morbid conditions and symptoms at presentation in 242 gram-negative prosthetic joint
infections sorted by surgical approach
Variables
All patients
N = 242 (100%)
Patients treated with DAIR
N = 174 (72%)
Patients not treated with DAIR
N = 68 (28%) p
Baseline features
Age, years; median (IQR range) 76 (68–81) 76 (69–81) 77 (65–81) 0.96
Sex, male 81 (34) 59 (34) 22 (32) 0.82
Diabetes mellitus 52 (22) 37 (21) 15 (22) 0.89
Chronic renal impairment 23 (10) 15 (9) 8 (12) 0.45
Use of steroids 21 (9) 16 (9) 5 (7) 0.65
Rheumatoid arthritis 19 (8) 12 (7) 7 (10) 0.37
Malignancy 16 (7) 13 (7) 3 (4) 0.57
Revision prosthesis 69 (29) 49 (28) 20 (29) 0.85
Prosthesis location
Hip 150 (62) 115 (66) 35 (51) 0.03
Knee 85 (35) 57 (33) 28 (41) 0.22
Other 7 (3) 2 (1) 5 (7) 0.02
Clinical presentation
Type of infection
Haematogenous PJI 37 (15) 24 (14) 13 (19) 0.30
Early postoperative PJI ≤30 days 152 (63) 130 (75) 22 (34) <0.001
Late chronic PJI >30 days 51 (21) 20 (11) 31 (46) <0.001
Positive intraoperative culture 2 (1) – 2 (1) –
Time to infection, daysa; median (IQR range) 16 (9–38) 14 (8–24) 349 (90–1307) <0.001
Bacteraemia 17 (7) 11 (6) 6 (9) 0.28
Pain 182 (75) 130 (75) 52 (76) 0.83
Inﬂammatory signs 172 (71) 130 (75) 42 (62) 0.046
Purulence drainage 139 (57) 113 (65) 26 (38) <0.001
Fever, temperature ≥38°C 81 (34) 62 (36) 19 (28) 0.25
Microbiological and laboratory data
Leukocytes, 109/L median (IQR range) 8.5 (6.5–11.0) 8.5 (6.1–11.0) 8.7 (7.0–10.8) 0.73
C-reactive protein, mg/Lb; median (IQR range) 23 (7–55) 21.8 (7–49) 36 (13–94) 0.14
Ciproﬂoxacin-susceptible isolates 200 (83) 139 (80) 61 (90) 0.03
Pseudomonas spp. infection 68 (28) 43 (25) 25 (37) 0.06
ESBL-GNB infection 19 (8) 16 (9) 3 (4) 0.22
Infection caused by two or more GNBs 40 (17) 33 (19) 7 (10) 0.10
Treatment
First surgical approach delay, daysc; median (IQR range) 6.5 (1–21) 5 (1–14) 24 (3–111) <0.001
≥2 debridements at any time 21 (8) 21 (12) – –
Polyethylene exchanged 96 (40) 96 (55) – –
No. patients treated with CP when all isolated GNBs
were susceptible
177 (73) 125 (71) 53 (78) 0.29
Outcome
Overall mortality 43 (18) 33 (19) 10 (15) 0.49
Mortality due to the infectione 12 (5) 5 (3) 7 (10) 0.12
CP, ciproﬂoxacin; DAIR, debridement, antibiotics and implant retention; ESBL-GNB, extended-spectrum beta-lactamase-producing gram-negative bacteria; GNB, gram-negative
bacteria.
Categorical data are expressed as absolute number (percentage) and continuous variables as median (interquartile range).
aTime to infection: time from prosthesis placement to onset of symptoms, excluding haematogenous infections.
bC-reactive protein value was available in 151 of 242 (62%) patients: 114 patients treated with DAIR and 37 not treated with DAIR.
cFirst surgical approach delay: time from onset of symptoms to surgery, excluding seven cases in which surgery was not performed.
dInformation on polyethylene exchange was only investigated in patients treated with DAIR: in 96 of 174 cases it was changed, in 47 it was not changed, and in 31 cases this
information was not available.
eDeaths attributed to PJI. All related deaths occurred within 30 days from the diagnosis.
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Patients with ESBL-producing strains were treated with a
carbapenem in 13 cases, tigecycline in two and piperacillin-ta-
zobactam in one patient with mixed infection due to
ESBL-E. coli and P. aeruginosa. Ciproﬂoxacin was added to a
carbapenem in two susceptible cases (combined therapy in 1
and sequential therapy in another patient). In patients who did
not fail, the median duration of antibiotic treatment in
ESBL-producing GNB-PJI was 62 days (IQR, 35–166). In those
who failed, failures were detected within 30 days while
antibiotics were ongoing in all except one case.
Outcome analysis
One patient with mixed infection by ESBL-producing E. coli and
P. aeruginosa was lost to follow-up. Among the 173 remaining
patients, failures were documented in 55/173 (32%): 39 (23%)
required implant removal, ﬁve (3%) died due to infec-
tion-related causes (median time from diagnosis to death,
13 days (IQR, 8–19)), four (2%) required long-course, sup-
pressive antimicrobial therapy, four (2%) had a persistent sinus
tract, and three (2%) needed a new debridement >30 days
after the initial one.
Global success rate with DAIR was 68% (118 patients) after
a median follow-up of 25 months (IQR, 15–39). In patients
with ciproﬂoxacin-susceptible GN-PJI treated with ciproﬂox-
acin, success was 79% (98/124), whereas in those with
susceptible infection not treated with ciproﬂoxacin, success
was 40% (6/15) (p 0.001). These two groups were comparable
with regard to all variables analysed except for age (data not
shown). The median age of patients with ciproﬂoxacin-sus-
ceptible GN-PJI was 75 years (IQR, 64–80) in those treated
with ciproﬂoxacin and 80 years (IQR, 77–87) in cases not
treated with ciproﬂoxacin (p 0.001). In ciproﬂoxacin-resistant
cases, the efﬁcacy of DAIR management was 41% (14/34).
The success rate in pseudomonal PJI was 79% (33 of 42
cases), which increased to 88% (29 of 33) when only
pseudomonal PJIs treated with ciproﬂoxacin were considered.
In infections caused by ESBL-producing Enterobacteriaceae,
success was 53% (eight of 15). Both cases treated with a
carbapenem and ciproﬂoxacin succeeded.
The Kaplan–Meier time-to-failure curve showed an associ-
ation with better outcome in patients treated with ciproﬂox-
acin (log rank ≤0.0001) (Fig. 1).
Potential risk factors in patients treated with DAIR who
succeeded or failed are outlined in Table 4. For the multivar-
iate analysis, a Cox regression model was ﬁtted to assess
whether ciproﬂoxacin treatment was predictive of DAIR
success. C-reactive protein at diagnosis and polyethylene
exchange were not included due to a signiﬁcant lack of data. In
susceptible GN-PJI, ciproﬂoxacin treatment exhibited an
independent protective effect (adjusted hazard ratio (aHR),
0.23; 95% CI, 0.13–0.40; p <0.001), whereas chronic renal
impairment was predictive of failure (aHR, 2.56; 95% CI, 1.14–
5.77; p 0.0232).
Regarding implementation of Zimmerli’s algorithm, failure
was signiﬁcantly higher in patients who did not meet the
criteria compared with those who did (35/75 (47%) vs. 20/98
(20%); p <0.001). Therefore, fulﬁllment of Zimmerli’s algo-
TABLE 3. Intravenous antimicrobial therapy used for 174
episodes of gram-negative prosthetic joint infections treated
with DAIR
Types of antimicrobial
therapy (drugs)
GN-PJI treated
with DAIR
N = 174 (100%)
Success rates for
each regimen
N = 173 (100%)a
Monotherapy (n = 126)
Non-carbapenem
beta-lactam, without
antipseudomonal activity
32 (18) 21/32 (66)
Carbapenem 31 (18) 18/31(58)
Other beta-lactams with
antipseudomonal activity
27 (16) 15/26 (58)a
Fluoroquinolones 28 (16) 21/28 (75)
Aztreonam 3 (2) 2/3 (67)
Other monotherapiesb 3 (2) 1/3 (33)
Combination therapy (n = 48)
Βeta-lactam with
antipseudomonal activity plus
ciproﬂoxacin
24 (14) 19/24 (79)
Carbapenem plus
ciproﬂoxacin
10 (6) 9/10 (90)
Beta-lactam without
antipseudomonal activity
plus ciproﬂoxacin
5 (3) 4/5 (80)
Beta-lactam with
antipseudomonal activity
plus aminoglycoside
6 (3) 5/6 (84)
Other combination
therapiesc
5 (3) 3/5 (60)
DAIR, debridement, antibiotics and implant retention; GN-PJI, gram-negative
prosthetic joint infection.
aOne patient was lost to follow-up; therefore outcome was evaluated in 173
patients.
bOther monotherapies included tigecycline in two cases and cotrimoxazole in one
case.
cOther combination therapies included ciproﬂoxacin plus cotrimoxazole in two
cases, beta-lactam plus cotrimoxazole in one case, colistin plus ciproﬂoxacin in one
case and aminoglycoside plus ciproﬂoxacin in one case.
TABLE 2. Microbiological ﬁndings in 174 patients with
gram-negative prosthetic joint infections treated with DAIR
Microorganisms
N = 174 episodes
with 211 isolates (100%)a
Enterobacteriaceae 162 (77)
Escherichia coli 63 (30)
Proteus spp. 31 (15)
Enterobacter spp. 29 (14)
Klebsiella spp. 14 (7)
Morganella morganii 10 (5)
Serratia marcescens 8 (4)
Salmonella spp. 5 (2)
Citrobacter spp. 2 (1)
Pseudomonas spp.b 43 (20)
Other gram-negative bacteria 6 (2)c
DAIR, debridement, antibiotics and implant retention; GNB, gram-negative
bacteria; GN-PJI, gram-negative prosthetic joint infection.
aAmong 174 episodes of GN-PJIs treated with DAIR, 34 were polymicrobial
infections caused by more than one GNB, accounting for a total of 211 isolates.
bPseudomonas aeruginosa in all but three cases, in which P. stuzeri was identiﬁed.
cOther GNB includes: three Bacteroides fragilis, one Pasteurella multocida, one
Alcaligenes xylosoxidans and one Rahnella aquatilis.
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rithm was a protective factor on univariate analysis (HR, 0.34
(0.20–0.59); p <0.0001). Focusing on patients who did not
meet Zimmerli’s algorithm, the failure rate was higher in those
with GNB-PJI due to ciproﬂoxacin-resistant GNB than in
susceptible cases (29/49 (59%) vs.6/26 (23%); p 0.03).
Discussion
To our knowledge, this is the largest reported case series of
PJI caused by GNB, which accounted for 12% of all PJIs in our
experience. The DAIR approach was used in 174 (72%) cases,
with an overall success rate of 68% that increased to 79% in
ciproﬂoxacin-susceptible GN-PJI treated with ciproﬂoxacin.
Thus, our results suggest that the DAIR strategy would be a
good initial surgical option in acute ciproﬂoxacin-susceptible
GN-PJI.
As is stated in the IDSA guidelines [20], debridement
without prosthesis removal is a feasible option for patients
with well-ﬁxed prostheses and acute infection. The efﬁcacy of
DAIR in GN-PJI has been investigated in limited series, and
reported success rates vary considerably: some authors
describe remission rates of only 27% [3], whereas others
report rates of 70% or higher [10,12,13,15,21]. These
differences in outcome have been attributed to several factors,
such as inclusion of chronic infection or P. aeruginosa infection
(which might yield higher recurrence rates), delay from
symptom onset after implant placement and differences in
ciproﬂoxacin use [3,10,13,14,18,21]. Our results are consis-
tent with those of Zmistowski et al. [15] and Martinez-Pastor
et al. [10], who reported remission rates of 70% and 74%,
respectively. Three years after that study, the same authors
[18] reported a drop in the rate to 64% after long-term
follow-up and considering aseptic loosening as failure, which
again concurs with our results. Regarding the delay from
symptom onset after implant placement, we highlighted that in
our series early infections occurred very early (median delay of
13 days), which is an element that may have facilitated the
procurement of good clinical results.
Notably, we found an 88% success rate in pseudomonal PJI
treated with ciproﬂoxacin. This ﬁnding supports the concept
that it is not the causative microorganism, but rather the
susceptibility to ciproﬂoxacin and ciproﬂoxacin use that
determines success in GN-PJI management. Therefore, cipro-
ﬂoxacin treatment should be considered the cornerstone
therapy for GN-PJI. The effectiveness of ciproﬂoxacin in these
patients can be attributed to its acceptable oral bioavailability,
optimal diffusion into synovial ﬂuid and bone, and activity
against bioﬁlms [16].
The increasing ciproﬂoxacin resistance rates amongGNB are
a cause for concern [22]. For this reason, we believe that
ciproﬂoxacin should be avoided as empirical treatment or as
initial treatment for acute infections with high bacterial load, not
only because of the risk of having a resistant strain, but also to
avoid the risk of inducing the development of ciproﬂoxacin
resistance. In our study, the efﬁcacy of DAIR in ciproﬂoxa-
cin-resistant cases dropped to 41%, a value similar to the 37%
(12/19) reported in a previous study [18]. In this situation, other
antibiotic options should be considered, but unfortunately,
there is little available information regarding alternatives in this
scenario [20,22]. Rifampin in combination with antibiotics that
permeabilize the bacterial membrane (e.g. colistin) has demon-
strated synergistic activity in vitro in GNB infection [23].
However, it has not been used in our patients and sufﬁcient
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FIG. 1. Kaplan–Meier estimates of the
cumulative risk of failure-free survival in
patients treated or not with ciproﬂoxacin.
Log-rank p ≤0.0001.
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published evidence to recommend this combination is lacking
[22]. In our study, ﬁve of ten patients treatedwith or switched to
cotrimoxazole without using ciproﬂoxacin were cured. None-
theless, there is little published clinical data regarding cotrim-
oxazole use in GN-PJI. Further clinical studies are needed to
clarify the value of drugs with good bone penetration such as
cotrimoxazole or fosfomycin as ciproﬂoxacin alternatives.
Not only ciproﬂoxacin-resistant GNB, but also other
multidrug-resistant GNBs, such as ESBL-producing Enterobac-
teriaceae, may have high failure rates. In our experience, 16/
174 GNB-PJIs treated with DAIR were caused by ESBL-pro-
ducing Enterobacteriaceae, and the success rate was 53%, a
percentage higher than the previous 42.8% (three out of seven
patients) reported value [11]. Only two of our cases were
treated with ciproﬂoxacin; hence the use of this drug in
susceptible ESBL-producing Enterobacteriaceae PJI could not
be evaluated. As ciproﬂoxacin resistance is common in
ESBL-producing GNB (69% in our series), other combinations,
such as carbapenems or colistin with fosfomycin, could be
explored because of the high anti-bioﬁlm activity and demon-
strated synergistic effect of fosfomycin in vitro and in a
foreign-body infection animal model [24,25].
Repeat debridement was performed in our series when
signs of infection persisted, and the need for two or more
debridements was predictive of DAIR failure on univariate
analysis. Although it is difﬁcult to separate this factor from
other risk variables, repeat debridement might indicate a more
complicated infection; therefore, prosthesis removal should be
considered.
Our analysis identiﬁed chronic renal insufﬁciency as a risk
factor for failure, a ﬁnding consistent with the observation of
other authors [26] that co-morbidities can impact the patient’s
outcome. Based on our results, we recommend careful
evaluation of the pros and cons of all surgical options in
patients with chronic renal failure.
In accordance with previous studies [27], our results
conﬁrm the applicability of Zimmerli’s algorithm, with a
success rate of 80% in patients fulﬁlling the criteria. It is even
more interesting that in patients who did not meet all the
criteria, ciproﬂoxacin use in susceptible cases was associated
with high success rates, again highlighting the favourable impact
of ciproﬂoxacin in GN-PJI.
The observational retrospective nature of our study is an
important limitation because of the potential drawbacks
implicit in this type of study design. In addition, it is a
multicentre study, which implies variability in the surgical
criteria, which could have some inﬂuence on a patient’s
outcome. Nonetheless, all centres included had a specialized
multidisciplinary team for the treatment of orthopaedic
infections, including infectious disease specialists, microbiolo-
gists and specialized orthopaedic surgeons, all of whom belong
to the same national medical societies and use the same clinical
and surgical criteria to evaluate patients.
In conclusion, we present the largest series of GN-PJI
managed with DAIR. Our results conﬁrm a 79% success rate in
ciproﬂoxacin-susceptible GN-PJI treated with debridement,
ciproﬂoxacin treatment and implant retention. Therefore the
DAIR strategy would be a good initial surgical option in acute
ciproﬂoxacin-susceptible GN-PJI with a stable implant. New
therapeutic strategies are needed for ciproﬂoxacin-resistant
infections.
TABLE 4. Univariate and multivariate analysis of parame-
ters predicting overall failure in 173 patients treated with
DAIR and known outcome
Unadjusted analysis Adjusted analysis
HR (95% CI) p aHR (95% CI) p
Male sex 0.99 (0.56–1.73) 0.9613 – –
Age (years) 1.03 (1.00–1.05) 0.0685 1.01 (0.13–1.04) 0.6000
Diabetes mellitus 1.28 (0.69–2.38) 0.4407 – –
Chronic renal
failure
2.14 (0.97–4.76) 0.0604 2.56 (1.14–5.77) 0.0232
Rheumatoid
arthritis
1.37 (0.55–3.45) 0.4988 – –
Use of steroids 1.32 (0.57–3.09) 0.5189 – –
Revision
prosthesis
1.04 (0.59–1.84) 0.8922 – –
Prosthesis
location, hip
1.52 (0.85–2.73) 0.1612 – –
Prosthesis
location, knee
0.69 (0.38–1.24) 0.2162 – –
Acute infection 0.80 (0.38–1.69) 0.5563 – –
Early postoperative
PJI (reference)
1 – –
Haematogenous
PJIs
0.90 (0.40–2.02) 0.8170 – –
Late chronic PJI 1.23 (0.58–2.64) 0.8170 – –
Bacteraemia due
to GNB
1.30 (0.46–3.62) 0.6205 – –
Fever 1.02 (0.59–1.79) 0.9321 – –
Local pain 0.84 (0.46–1.55) 0.5780 – –
External
inﬂammatory
signs
1.11 (0.60–2.07) 0.7411 – –
Purulence 1.49 (0.83–2.67) 0.1796 1.64 (0.91–2.98) 0.1002
Polymicrobial PJI 1.18 (0.61–2.29) 0.6201 – –
Pseudomonas spp.
PJI
0.59 (0.29–1.20) 0.1440 – –
GNB susceptible
to CP
0.31 (0.18–0.54) 0.0000 – –
ESBL-GNB PJI 1.73 (0.78–3.82) 0.1773 – –
CRP at diagnosis,
per 100 mg/La
1.00 (1.001–1.007) 0.016 – –
Leukocyte count,
109/L
1.005 (0.951–1.061) 0.8684 – –
Need for ≥2
debridementsb
2.15 (1.11–4.18) 0.0237 – –
Debridement
delay, daysc
1.004 (0.996–1.013) 0.2835 – –
Polyethylene
exchangea
0.73 (0.35–1.51) 0.3994 – –
Treatment with
CP
0.22 (0.13–0.37) 0.0000 0.23 (0.13–0.40) 0.0000
Combined
antibiotic
therapy
0.42 (0.21–0.87) 0.0189 0.52 (0.25–1.06) 0.0735
CI, conﬁdence interval; CP, ciproﬂoxacin; CPR, C-reactive protein (mg/L);
ESB-GNB, extended-spectrum beta-lactamase-producing gram-negative bacteria;
HR, hazard ratio; GNB, gram-negative bacilli; PJI, prosthetic joint infection.
aMultivariate analyses do not include CPR at diagnosis or polyethylene exchange,
due to signiﬁcant lack of data.
bNeed for ≥2 debridements at any time since diagnosis.
cDebridement delay: days from onset of symptoms to debridement.
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Appendix 1
The REIPI Group for the Study of Prosthetic Joint Infection
also includes: Carles Amat, M Nieves Larrosa and Mireia Puig
(Hospital Universitari Vall d’Hebron, Barcelona, Spain); Oscar
Murillo, Xavier Cabo (Hospital Universitario de Bellvitge,
Barcelona, Spain); Miguel Angel Goenaga, Maitane Elola and
Gaspar de la Herran and Jose Mª Garcia- Arenzana (Hospital
Universitario Donostia, San Sebastian, Spain); Sebastian
Garcıa-Ramiro, Juan Carlos Martınez-Pastor and Eduard
Tornero (Hospital Clınic i Provincial, Barcelona, Spain); Juan
Manuel Garcıa-Lechuz, Mercedes Marın and Manuel Villanueva
(Hospital Universitario Gregorio Mara~non, Madrid, Spain);
I~nigo Lopez, Ramon Cisterna and Juan Miguel Santamarıa
(Hospital de Basurto, Bilbao, Spain); Marıa-Jose Gomez,
Andres Puente y Pedro Cano (Hospital Universitario Virgen
del Rocıo, Sevilla, Spain); Juan Pablo Horcajada, Paula
Gonzalez-Mınguez, Eugenia Portillo and Lluis Puig (Hospital
del Mar, Barcelona, Spain); Marıa Franco, Marcos Jordan and
Pere Coll (Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain); Juan Amador-Mellado, Carlos Fuster-Foz, Luis
Garcıa-Paıno (Hospital El Bierzo, Ponferrada, Spain); Isabel
Nieto, Miguel Angel Muniain and Ana Isabel Suarez (Hospital
Universitario Virgen Macarena, Sevilla, Spain); Julia Praena,
Marıa-Jose Gomez and Andres Puente (Hospital Universitario
Virgen del Rocıo, Sevilla, Spain); Marıa Antonia Maseguer,
Eduardo Garagorri and Vicente Pintado (Hospital Universitario
Ramon y Cajal, Madrid, Spain); Carmen Marinescu, Antonio
Ramırez and Francisco Montaner (Hospital Universitario Son
Dureta, Palma de Mallorca, Spain); Elena Mu~nez, Teresa
Alvarez and Rodrigo Garcıa (Hospital Universitario Puerta
de Hierro, Madrid, Spain); Elena Puente, Carlos Salas y Marıa
Carmen Fari~nas (H. U. Marques de Valdecilla, Bilbao, Spain);
Josu Merino Perez, Bego~na Vilar Achabal and Jose Miguel
Montejo Baranda (Hospital Universitario Cruces, Bilbao,
Spain).
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